| Originator: |
|
DHSC & NHS England and Improvement: Supply disruption alert
|
|
|
|
- Care Trusts
- Mental Health Trusts
- Specialists Trusts
- Learning Disabilities Trusts
- Mental Health & Social Care Trusts
- Ambulance Trusts
- Mental Health & Learning Disabilities Trusts
- Acute Trusts
- Community Trusts
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- Special Health Authorities
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- DHSC Supply Disruption - Medicines
|
| Title: |
|
Methylprednisolone powder for solution for injection (all strengths) - Supply disruption
|
| Broadcast content: |
|
Any organisations using methylprednisolone in the management of Acute
Respiratory Distress Syndrome in COVID-19
patients should review guidance immediately and switch to an alternative agent. The alternative agents highlighted in
this alert are in good supply and can support full forecasted demand.
Given the links to COVID-19 we have sent this alert to a broader mailing list than would usually receive a Supply Disruption Alert of this type.
|
| Additional information: |
|
This alert is not relevant to Primary Care.
|
| Action underway deadline: |
|
18-Jan-2021
|
| Action complete deadline: |
|
20-Jan-2021
|